Anti-coagulant Pradaxa Boosts Cardiac Danger

Wednesday, 11 Jan 2012 12:04 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Boehringer Ingelheim GmbH’s anti-coagulant Pradaxa increases a patient’s risk of heart attack or severe chest pain, according to a review of studies conducted on the drug.
An analysis of seven clinical trials found that it was “significantly associated with a higher risk” of heart attacks and acute coronary syndrome, or ACS, a designation that includes heart attacks and chest pain, researchers wrote in a report published today in the Archives of Internal Medicine.
The potential risk of heart attacks could lead doctors to favor Pradaxa’s rivals such as Johnson & Johnson and Bayer AG's blood-thinner Xarelto in a market Leerink Swann analysts estimate to be valued at $9 billion a year.
While Pradaxa appears to prevent patients with erratic heartbeat from having strokes, “clinicians should consider the potential of these serious harmful cardiovascular effects” when prescribing the medicine, said Ken Uchino and Adrian V. Hernandez, both physicians at the Cleveland Clinic in Ohio, in the report.
Of 20,000 patients taking Pradaxa, 237 had a heart attack or chest pain, compared with 83 patients out of 10,514 on the standard drug warfarin or a placebo, Uchino and Hernandez wrote.
The U.S. Food and Drug Administration said last month it would evaluate the Pradaxa studies following reports of serious bleeding events in patients.
Boehringer, based in Ingelheim, Germany, beat New Brunswick, New Jersey-based J&J and Bayer to the atrial fibrillation market. The drugs are vying to become the dominant replacement for warfarin, the half-century old standard of care for preventing blood clots in heart attack victims and other patients. Pfizer and New York-based Bristol-Myers Squibb are seeking approval for their rival pill, known as Eliquis.
Copyright Bloomberg News





© HealthDay

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Comments
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved